A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab.

Trial Profile

A Multicenter Open-Label Continuation Study in Moderate to Severe Chronic Plaque Psoriasis Subjects Who Completed a Preceding Psoriasis Clinical Study With Adalimumab.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2018

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
    • 15 Jun 2013 Planned number of patients changed from 1469 to 1500 as reported by European Clinical Trials Database.
    • 18 Nov 2010 Additional locations added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top